The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis
Open accessAbstract
BACKGROUND: Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. METHODS: A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection. RESULTS: Ten primary articles and 1 conference abstract met the inclusion criteria. Across 6 studies (comprising 314 drug users, of whom 141 [45%] were PWID), pooled SVR was 56% (95% confidence interval [CI], 50%-61%) for all genotypes, 37% (95% CI, 26%-48%) for genotypes 1/4, and 67% (95% CI, 56%-78%) for genotypes 2/3. Pooled 80/80/80 adherence was 82% (95% CI, 74%-89%) across 2 studies, and pooled treatment discontinuation was 22% (95% CI, 16%-27%) across 4 studies. Across 5 studies (comprising 131 drug users) examining reinfection, pooled risk was 2.4 (95% CI, .9-6.1) per 100 person-years. CONCLUSIONS: HCV treatment outcomes are acceptable in PWID, supporting treatment guidelines. The pooled estimate of HCV reinfection risk was low, but there was considerable uncertainty around this estimate. Further studies on the risk of reinfection are needed to assess the long-term effectiveness of HCV treatment in PWID.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2014) · Medical Entomology and Zoology · Cited by 17,633
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., Dienstag, J., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Open access publishing takes off
Delamothe, T., & Smith, R. (2004) · BMJ · doi:10.1136/bmj.328.7430.1 · Cited by 299
Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence
Hellard, M., Sacks‐Davis, R., & Gold, J. (2009) · Clinical Infectious Diseases · doi:10.1086/600304 · Cited by 232
Self-citationMartin, N. K., Vickerman, P., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.029 · Cited by 230
Self-citationOvercoming Barriers to Prevention, Care, and Treatment of Hepatitis C in Illicit Drug Users
Edlin, B. R., Kresina, T. F., Raymond, D. B., Carden, M. R., Gourevitch, M. N., Rich, J. D., Cheever, L. W., & Cargill, V. A. (2005) · Clinical Infectious Diseases · doi:10.1086/427441 · Cited by 192
Veldt, B. J., Saracco, G., Boyer, N., Cammà, C., Bellobuono, A., Hopf, U., Castillo, I., Weiland, O., Nevens, F., Hansen, B. E., et al. (2004) · Gut · doi:10.1136/gut.2003.038257 · Cited by 174
What Is Killing People with Hepatitis C Virus Infection?
Grebely, J., & Dore, G. J. (2011) · Seminars in Liver Disease · doi:10.1055/s-0031-1297922 · Cited by 145
Self-citationEffective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection
Dore, G. J., Hellard, M. E., Matthews, G. V., Grebely, J., Haber, P., Petoumenos, K., Yeung, B., Marks, P. S., van Beek, I., McCaughan, G. W., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.019 · Cited by 140
Self-citationTreatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-Up
Dalgård, O., Bjøro, K., Hellum, K. B., et al. (2002) · European Addiction Research · doi:10.1159/000049487 · Cited by 129
Reinfection with hepatitis C virus following sustained virological response in injection drug users
Grebely, J., Knight, E., Ngai, T., Genoway, K. A., Raffa, J. D., Storms, M. M., Gallagher, L., Krajden, M., Dore, G. J., Duncan, F., et al. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06238.x · Cited by 82
Self-citationCurrie, S. L., Ryan, J. C., Tracy, D., Wright, T. L., George, S., McQuaid, R., Kim, M., Shen, H., & Monto, A. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.09.011 · Cited by 63
Weiss, J. J., Bräu, N., Stivala, A. C., Swan, T., & Fishbein, D. A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04004.x · Cited by 60
Wilkinson, M., CRAWFORD, V., Tippett, A., Jolly, F., Turton, J. R. H., SIMS, E., Hekker, M. D., DALTON, J., Marley, R., & Foster, G. R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03834.x · Cited by 52
Surveillance for newly acquired hepatitis C in Australia
Robotin, M. C., COPLAND, J., Tallis, G. F., et al. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2003.03270.x · Cited by 47
Borroni, G., Andreoletti, M., Casiraghi, M. A., Ceriani, R., Guerzoni, P., Omazzi, B., Terreni, N. M., & Salerno, F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03657.x · Cited by 46
Alvarez‐Uria, G., Day, J., Jafar, A. J. N., Russell, S. K., & Vilar, F. J. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01958.x · Cited by 44
Zanini, B., Covolo, L., Donato, F., & Lanzini, A. (2010) · Clinical Therapeutics · doi:10.1016/s0149-2918(11)00021-x · Cited by 32
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Public health and international drug policy
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00619-x · Cited by 641
Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., Ferguson, J., Forton, D., Foster, G., Gilmore, S. I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61838-9 · Cited by 602
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Self-citation
Metadata
- Authors
- Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., Goldberg, D. J., & Hellard, M. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-15
- Volume
- 57
- Issue
- suppl_2
- Pages
- S80-S89
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2006747389
- Cited by
- 309
- References
- 24
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.